258 related articles for article (PubMed ID: 14521410)
21. An Aggregation Advisor for Ligand Discovery.
Irwin JJ; Duan D; Torosyan H; Doak AK; Ziebart KT; Sterling T; Tumanian G; Shoichet BK
J Med Chem; 2015 Sep; 58(17):7076-87. PubMed ID: 26295373
[TBL] [Abstract][Full Text] [Related]
22. A printable hydrogel microarray for drug screening avoids false positives associated with promiscuous aggregating inhibitors.
Mateen R; Ali MM; Hoare T
Nat Commun; 2018 Feb; 9(1):602. PubMed ID: 29426913
[TBL] [Abstract][Full Text] [Related]
23. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
24. Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures.
Feng BY; Shoichet BK
J Med Chem; 2006 Apr; 49(7):2151-4. PubMed ID: 16570910
[TBL] [Abstract][Full Text] [Related]
25. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Guglietta A; Palacín C; Casals J; del Valle O; Guardià C; Rodríguez V; Quindós G
Chemotherapy; 2004 Dec; 50(6):308-13. PubMed ID: 15608448
[TBL] [Abstract][Full Text] [Related]
26. Stability and equilibria of promiscuous aggregates in high protein milieus.
Coan KE; Shoichet BK
Mol Biosyst; 2007 Mar; 3(3):208-13. PubMed ID: 17308667
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals.
Rodriguez RJ; Acosta D
J Biochem Toxicol; 1996; 11(3):127-31. PubMed ID: 9029271
[TBL] [Abstract][Full Text] [Related]
28. Epoxyethane-/ethynesulfonamides with antifilarial activities. Degradation kinetics and inhibitory effect on filarial malate dehydrogenase and lactate dehydrogenase.
Radembino N; Loiseau PM; Dessalles MC; Marchat L; Bories C; Gayral P; Mahuzier G
Arzneimittelforschung; 1998 Mar; 48(3):294-9. PubMed ID: 9553689
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.
Kinobe RT; Dercho RA; Vlahakis JZ; Brien JF; Szarek WA; Nakatsu K
J Pharmacol Exp Ther; 2006 Oct; 319(1):277-84. PubMed ID: 16807364
[TBL] [Abstract][Full Text] [Related]
30. Gallotannins are non-specific inhibitors of α-amylase: Aggregates are the active species taking part in inhibition.
Szabó K; Hámori C; Gyémánt G
Chem Biol Drug Des; 2021 Feb; 97(2):349-357. PubMed ID: 32889761
[TBL] [Abstract][Full Text] [Related]
31. Docking analysis of a series of cytochrome P-450(14) alpha DM inhibiting azole antifungals.
Talele TT; Hariprasad V; Kulkarni VM
Drug Des Discov; 1998 May; 15(3):181-90. PubMed ID: 9689500
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.
Monostory K; Hazai E; Vereczkey L
Chem Biol Interact; 2004 Apr; 147(3):331-40. PubMed ID: 15135088
[TBL] [Abstract][Full Text] [Related]
33. Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum.
Tzatzarakis MN; Tsatsakis AM; Charvalos E; Vakalounakis D
J Environ Sci Health B; 2001 May; 36(3):331-40. PubMed ID: 11411855
[TBL] [Abstract][Full Text] [Related]
34. Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
Tani N; Rahnasto-Rilla M; Wittekindt C; Salminen KA; Ritvanen A; Ollakka R; Koskiranta J; Raunio H; Juvonen RO
Eur J Med Chem; 2012 Jan; 47(1):270-7. PubMed ID: 22100140
[TBL] [Abstract][Full Text] [Related]
35. Catechol-rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR).
Zinglé C; Tritsch D; Grosdemange-Billiard C; Rohmer M
Bioorg Med Chem; 2014 Jul; 22(14):3713-9. PubMed ID: 24890653
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
[TBL] [Abstract][Full Text] [Related]
37. Flavonoids: true or promiscuous inhibitors of enzyme? The case of deoxyxylulose phosphate reductoisomerase.
Tritsch D; Zinglé C; Rohmer M; Grosdemange-Billiard C
Bioorg Chem; 2015 Apr; 59():140-4. PubMed ID: 25800132
[TBL] [Abstract][Full Text] [Related]
38. Turning promiscuous kinase inhibitors into safer drugs.
Zhang X; Crespo A; Fernández A
Trends Biotechnol; 2008 Jun; 26(6):295-301. PubMed ID: 18403035
[TBL] [Abstract][Full Text] [Related]
39. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.
Gibbs MA; Kunze KL; Howald WN; Thummel KE
Drug Metab Dispos; 1999 May; 27(5):596-9. PubMed ID: 10220488
[TBL] [Abstract][Full Text] [Related]
40. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
Mendgen T; Steuer C; Klein CD
J Med Chem; 2012 Jan; 55(2):743-53. PubMed ID: 22077389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
